



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Hu et al.

Docket No.: PF112P2D1

Application No.: 09/219,442

Confirmation No.: 4797

Filed: December 23, 1998

Art Unit: 1647

For: Vascular Endothelial Growth Factor 2

Examiner: R.S. Landsman

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references FU-GF listed on the attached Form PTO/SB/08. Copies of references FX-GD are enclosed.

Copies of references GE and GF were submitted by Applicants as references ER and EW, respectively, in an Information Disclosure Statement submitted by Applicants on March 16, 2001, and therefore are not provided herewith. The publication dates of the references were inadvertently omitted in the original submission. Applicants respectfully correct that omission with this paper.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the

PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.


Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

The undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that references FX-GB contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Information Disclosure Statement. In particular, the references were cited in Supplementary Partial European Search Reports (references GC and GD, respectively) dated October 25, 2004 and November 8, 2004, respectively, in connection with corresponding international applications.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge such fee to our Deposit Account No. 08-3425.


Dated: January 21, 2005

Respectfully submitted,

By 
Michele M. Wales

Registration No.: 43,975
HUMAN GENOME SCIENCES, INC.
Intellectual Property Dept.
14200 Shady Grove Road
Rockville, Maryland 20850
(301) 610-5772

MMW/MJP/DBS/ba



PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	PF112P2D1
-------	---	----	---	------------------------	-----------

Complete if Known

Application Number	09/219,442-Conf. #4797
Filing Date	December 23, 1998
First Named Inventor	Jing-Shan Hu
Art Unit	1647
Examiner Name	R.S. Landsman
Attorney Docket Number	PF112P2D1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	FU	6,734,285	05-11-2004	Hu et al.	
	FV	04/0143103	07-22-2004	Hu et al.	
	FW	02/0120123	08-29-2002	Rosen et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	FX	WO-95/24473	09-14-1995	Human Genome Sciences, Inc.		
	FY	WO-97/19694	06-05-1997	Amgen, Inc.		
	FZ	WO-97/00271	01-03-1997	The Regents of the University of California		
	GA	WO-97/08320	03-06-1997	Morphosys Gesellschaft Fur Proteinoptimier Ung MBH		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	GB	YANG et al., "Flk-1, a Receptor for Vascular Endothelial Growth Factor (VEGF), Is Expressed by Retinal Progenitor Cells," <i>J. Neuroscience</i> , 16(19):6089-6099 (Oct. 1, 1996).	
	GC	Supplementary European Search Report, Application No. EP 02 72 6730, mailed October 25, 2004.	
	GD	Supplementary European Search Report, Application No. EP 00 90 5992, mailed November 8, 2004.	
	GE	LITWIN et al., "Role of Cytokines in Endothelial Cell Functions," <i>Human Cytokines</i> 101-129 (1995).	
	GF	WALSH et al., "Gene Therapy for Human Hemoglobinopathies," <i>P.S.E.B.M.</i> 204: 289-300 (1993).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------